Clinical Commander

Back to dossier
cardio.hypertensive-emergency.post-renal-transplant.v1PRODUCTION
cardio.hypertensive-emergency.post-renal-transplant.v1

Hypertensive emergency in kidney transplant recipient (CNI / rejection / TRAS / native disease recurrence)

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

HTN emergency in kidney transplant — multifactorial etiology (CNI vasoconstriction + volume + acute rejection + TRAS + native disease recurrence + steroid burst). Drug profile pivots: nicardipine first-line (renal-friendly DHP-CCB; minimal CYP3A4); AVOID nitroprusside if eGFR <30 (cyanide accumulation); AVOID ACEi/ARB if rising Cr (worsens AKI); AVOID diltiazem/verapamil long-term (CYP3A4 — increases CNI levels); statin interactions matter (pravastatin/fluvastatin/rosuvastatin preferred). Critical workup: STAT renal Doppler for TRAS + CMV/BK PCR + DSA for rejection + biopsy if Cr rising. Route to parent engine for shared HTN-emergency arc + nephrology + transplant team for graft management.

Inputs
5
Actions
0
Advance rule
Set
Advance when

transplant context + CNI level + Cr trajectory characterized

Patient inputs (13)

Older recipients have higher CV risk; influences AC + statin selection (KDIGO 2009)

Time post-transplant drives differential — early (<3 mo) acute rejection / surgical complication / hyperacute; intermediate (3 mo - 2 yr) TRAS peak / chronic rejection / CNI accumulation; late (>2 yr) chronic rejection / recurrence / CNI-related CKD

Tacrolimus vs cyclosporine vs everolimus drives drug interaction profile (CYP3A4 substrate); prednisone burst is HTN driver; MMF level relevant

Acute Cr rise differentiates rejection (rising) from CNI toxicity (often stable / mild rise) from TRAS (variable); drives biopsy decision

Supratherapeutic CNI = drug toxicity HTN; subtherapeutic = under-immunosuppression → rejection risk

CMV reactivation can drive rejection / vasculopathy; especially if D+/R- mismatch + within 1 yr of prophylaxis stop

STAT renal Doppler — rule out TRAS (peak 3 mo - 2 yr post-transplant); RI elevation suggests AMR or TRAS; flow pattern + waveform analysis

Defines crisis threshold (≥180); KDIGO target outpatient <130/80 in transplant

DBP ≥120 supports emergency; component of MAP

DSA presence + rising Cr → antibody-mediated rejection (AMR) workup → biopsy + plasmapheresis ± rituximab ± IVIG (Banff 2019)

CTA preferred over MRA in eGFR <30 (NSF risk with gadolinium); MRA if eGFR ≥30 or contrast allergy; angiography for confirmation + intervention

Banff 2019 classification — biopsy if rising Cr + DSA + clinical suspicion of rejection; risks bleeding + graft loss; usually after Doppler + serology

BK virus nephropathy can present with rising Cr + HTN; blood + urine PCR; treatment differs from rejection (reduce IS rather than treat)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningacute_rejection_on_biopsy
    Biopsy-proven acute rejection (Banff 2019: borderline / IA / IB / IIA / IIB / III for cellular; pAMR 1 / 2 / 3 for AMR) with HTN + rising Cr
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereTRAS_confirmed_on_imaging
    Transplant renal artery stenosis confirmed on CTA / MRA / angiography in patient with refractory HTN + graft dysfunction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereAKI_from_ACEi_ARB_exposure_error
    Acute Cr rise after ACEi/ARB initiation in transplant — efferent arteriolar vasodilation worsens AKI in graft hypoperfusion (volume depletion / TRAS / acute rejection)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredrug_interaction_missed_CYP3A4
    New CYP3A4 inhibitor (azole antifungal, macrolide, diltiazem, verapamil, grapefruit) added to CNI regimen → tacrolimus level surge → toxicity HTN + AKI
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

HTN emergency in kidney transplant — etiology-specific (CNI toxicity / rejection / TRAS / volume / native disease) + drug-interaction-aware
axis: htn_post_renal_transplant_etiology_specific
Selected axis "HTN emergency in kidney transplant — etiology-specific (CNI toxicity / rejection / TRAS / volume / native disease) + drug-interaction-aware" by default fallback (first axis)
  • nicardipine
    first line
    DHP_CCB
    5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h • IV • continuous
    triggers: transplant_HTN_emergency, CNI_toxicity_HTN, volume_overload_HTN
    KDIGO 2020 BP transplant first-line — renal-friendly DHP-CCB; minimal CYP3A4 effect on tacrolimus (unlike diltiazem/verapamil); predictable titration; preserves graft perfusion
    rxcui 7396
  • labetalol
    second line
    mixed_alpha_beta_blocker
    20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion • IV • bolus or infusion
    triggers: transplant_HTN_with_tachycardia, nicardipine_intolerant
    KDIGO 2020 second-line — mixed α/β; useful when sympathetic drive high; minimal CNI interaction
    rxcui 6185
  • amlodipine
    first line
    DHP_CCB
    5-10 mg PO daily • PO • daily
    triggers: transplant_HTN_oral_transition, long_term_BP_target_lt_130
    KDIGO 2020 long-term first-line — DHP-CCB; minimal CYP3A4 interaction; does NOT increase rejection (legacy concern disproven); proven safe in transplant cohorts
    rxcui 17767
  • lisinopril
    add on
    ACE_inhibitor
    5 mg PO daily, titrate to 10-40 mg • PO • daily
    triggers: stable_Cr_post_acute_phase, proteinuria_present, native_disease_recurrence
    KDIGO 2020 — add ACEi/ARB AFTER acute phase resolves + Cr stable × 7 d; reno-protective in proteinuric nephropathy; HOLD acutely if rising Cr
    rxcui 29046
  • empagliflozin
    add on
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: transplant_with_DM_or_proteinuria, eGFR_gte_25
    EMPA-KIDNEY 2023 — reno-protective in CKD; emerging evidence in transplant (DAPA-CKD post-hoc subgroup); avoid if active UTI or recent transplant <3 mo (caution)
    rxcui 1545653
  • AVOID nitroprusside if eGFR <30
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: transplant_with_egfr_lt_30
    Cyanide / thiocyanate accumulation in renal impairment; ACC/AHA 2025 AVOID in eGFR <30; common pitfall in transplant cohort given graft dysfunction
  • AVOID ACEi/ARB acutely if rising Cr
    contraindication substitute
    do_not_use
    HOLD ACUTELY • N/A • N/A
    triggers: transplant_with_rising_Cr_or_acute_rejection
    Efferent arteriolar vasodilation worsens AKI in volume-depleted or rejecting graft; KDIGO 2020 — restart only after Cr stable × 7 d with q3-7d monitoring
  • AVOID diltiazem/verapamil long-term as monotherapy
    contraindication substitute
    do_not_use_with_caveat
    AVOID OR INTENTIONAL DOSE-SPARING • N/A • N/A
    triggers: CNI_dose_optimization
    CYP3A4 inhibition increases tacrolimus 30-50% — sometimes used INTENTIONALLY to reduce CNI dose (cost / nephrotoxicity reduction); requires close trough monitoring; not for de novo HTN management

outpatient playbook — drug actions (1)

  1. 1. continue 4-tier regimen + CNI + statin
    rxcui 17767
    Amlodipine 5-10 + lisinopril 10-40 + tacrolimus + pravastatin 40 • PO • as scheduled
    trigger: Stable maintenance
    KDIGO 2020

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Kidney transplant recipient + new SBP ≥180 OR DBP ≥120 (or ≥30 mmHg above baseline) — multifactorial etiology screen (KDIGO 2020 BP transplant); Transplant + acute Cr rise (≥25% from baseline) + new severe HTN → suspect acute rejection / TRAS / CNI toxicity; Transplant + recent CNI dose change / new CYP3A4 interaction (azole, macrolide, diltiazem) → drug-interaction-driven HTN.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Hypertensive emergency in kidney transplant recipient (CNI / rejection / TRAS / native disease recurrence)** (cardio.hypertensive-emergency.post-renal-transplant.v1).
Scope: HTN emergency in kidney transplant — multifactorial etiology (CNI vasoconstriction + volume + acute rejection + TRAS + native disease recurrence + steroid burst). Drug profile pivots: nicardipine first-line (renal-friendly DHP-CCB; minimal CYP3A4); AVOID nitroprusside if eGFR <30 (cyanide accumulation); AVOID ACEi/ARB if rising Cr (worsens AKI); AVOID diltiazem/verapamil long-term (CYP3A4 — increases CNI levels); statin interactions matter (pravastatin/fluvastatin/rosuvastatin preferred). Critical workup: STAT renal Doppler for TRAS + CMV/BK PCR + DSA for rejection + biopsy if Cr rising. Route to parent engine for shared HTN-emergency arc + nephrology + transplant team for graft management.

No severity triggers fired against current inputs.

Plan

Regimen axis: **HTN emergency in kidney transplant — etiology-specific (CNI toxicity / rejection / TRAS / volume / native disease) + drug-interaction-aware**.
1. nicardipine 5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h IV continuous (DHP_CCB, first line) — KDIGO 2020 BP transplant first-line — renal-friendly DHP-CCB; minimal CYP3A4 effect on tacrolimus (unlike diltiazem/verapamil); predictable titration; preserves graft perfusion
2. labetalol 20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion IV bolus or infusion (mixed_alpha_beta_blocker, second line) — KDIGO 2020 second-line — mixed α/β; useful when sympathetic drive high; minimal CNI interaction
3. amlodipine 5-10 mg PO daily PO daily (DHP_CCB, first line) — KDIGO 2020 long-term first-line — DHP-CCB; minimal CYP3A4 interaction; does NOT increase rejection (legacy concern disproven); proven safe in transplant cohorts
4. lisinopril 5 mg PO daily, titrate to 10-40 mg PO daily (ACE_inhibitor, add on) — KDIGO 2020 — add ACEi/ARB AFTER acute phase resolves + Cr stable × 7 d; reno-protective in proteinuric nephropathy; HOLD acutely if rising Cr
5. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, add on) — EMPA-KIDNEY 2023 — reno-protective in CKD; emerging evidence in transplant (DAPA-CKD post-hoc subgroup); avoid if active UTI or recent transplant <3 mo (caution)
6. AVOID nitroprusside if eGFR <30 AVOID N/A N/A (do_not_use, contraindication substitute) — Cyanide / thiocyanate accumulation in renal impairment; ACC/AHA 2025 AVOID in eGFR <30; common pitfall in transplant cohort given graft dysfunction
7. AVOID ACEi/ARB acutely if rising Cr HOLD ACUTELY N/A N/A (do_not_use, contraindication substitute) — Efferent arteriolar vasodilation worsens AKI in volume-depleted or rejecting graft; KDIGO 2020 — restart only after Cr stable × 7 d with q3-7d monitoring
8. AVOID diltiazem/verapamil long-term as monotherapy AVOID OR INTENTIONAL DOSE-SPARING N/A N/A (do_not_use_with_caveat, contraindication substitute) — CYP3A4 inhibition increases tacrolimus 30-50% — sometimes used INTENTIONALLY to reduce CNI dose (cost / nephrotoxicity reduction); requires close trough monitoring; not for de novo HTN management

Setting playbook (outpatient) — Long-term transplant + cardiology surveillance — BP <130/80 maintained, CNI optimization, rejection / TRAS / recurrence surveillance, CV risk reduction (CV is #1 cause of death in transplant)
9. continue 4-tier regimen + CNI + statin Amlodipine 5-10 + lisinopril 10-40 + tacrolimus + pravastatin 40 PO as scheduled — Stable maintenance (KDIGO 2020)

Non-pharmacologic actions:
- DASH + lifestyle maintenance
- Smoking cessation + weight management
- Annual nephrology + transplant + cardiology follow-up
- Annual dermatology for skin cancer screen

AVOID / contraindication checks:
- Nitroprusside_avoid_in_egfr_lt_30_cyanide (ACC/AHA 2025; common in transplant)
- Acei_arb_hold_acutely_if_rising_Cr_or_rejection (KDIGO 2020 BP transplant)
- Diltiazem_verapamil_increases_tacrolimus_avoid_unless_intentional (KDIGO 2020)
- Gadolinium_NSF_risk_if_egfr_lt_30_for_MRA (FDA black box)
- NSAIDs_avoid_in_transplant_AKI_risk (KDIGO 2009 transplant)
- Graft_perfusion_preservation_gentle_titration_no_overshoot (KDIGO 2020)

Monitoring

Regimen monitoring:
- arterial line q5-15min BP (ACC/AHA 2025)
- q4-6h BMP for K and Cr (KDIGO 2020)
- q12h CNI trough during titration (KDIGO 2009)
- CMV BK PCR per local protocol (AST consensus)
- DSA baseline then per AMR treatment (Banff 2019)
- daily Doppler if TRAS (KDIGO 2009)
- serial creatinine q4-6h (KDIGO 2020)
- long term BP target lt 130 80 (KDIGO 2020)

Setting (outpatient) monitoring:
- Quarterly BP + Cr + CNI
- Annual lipid + A1c + DSA
- Annual cardiac risk assessment

Follow-up plan: Transition to oral 4-tier ladder once stable × 12-24 h (amlodipine + thiazide-like + ACEi/ARB once Cr stable + BB if cardiac indication); long-term BP target <130/80 per KDIGO 2020; lifelong CNI level monitoring (q1-3 mo); annual cardiac surveillance (CV is leading cause of death in transplant); CMV/BK PCR per local protocol; DSA monitoring annually; vaccination updates (avoid live); cancer surveillance (skin, PTLD)
- Close-out criterion: oral regimen stable + nephrology + transplant + cardiology surveillance plan in place

Monitoring phase: A-line + q5-15 min BP; q4-6h BMP for K + Cr (Cr trajectory drives ACEi/ARB restart timing); q12h CNI trough during titration; serial CBC; UOP + dialysis access if oliguric; daily Doppler if TRAS; serial DSA if AMR treatment; serial CMV/BK PCR if viral driver

Disposition

Current setting: outpatient — Long-term transplant + cardiology surveillance — BP <130/80 maintained, CNI optimization, rejection / TRAS / recurrence surveillance, CV risk reduction (CV is #1 cause of death in transplant)

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + nephrology transplant clinic

Escalation triggers (move to higher acuity):
- BP rebound → return to ED
- Cr rise → nephrology urgent
- New cardiac symptoms → cardiology urgent

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Biopsy-proven acute rejection (Banff 2019: borderline / IA / IB / IIA / IIB / III for cellular; pAMR 1 / 2 / 3 for AMR) with HTN + rising Cr
- [SEVERE] Transplant renal artery stenosis confirmed on CTA / MRA / angiography in patient with refractory HTN + graft dysfunction
- [SEVERE] Acute Cr rise after ACEi/ARB initiation in transplant — efferent arteriolar vasodilation worsens AKI in graft hypoperfusion (volume depletion / TRAS / acute rejection)

Citations

- KDIGO 2020 BP Management in Kidney Transplant Recipients + KDIGO 2009 Transplant Recipient Care (Kasiske AJT 2010 PMID 19845597) + 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) [PMID:19845597](https://pubmed.ncbi.nlm.nih.gov/19845597/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 32249009) [PMID:32249009](https://pubmed.ncbi.nlm.nih.gov/32249009/)
- Cited evidence (PMID 26551272) [PMID:26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/)
- Cited evidence (PMID 10972386) [PMID:10972386](https://pubmed.ncbi.nlm.nih.gov/10972386/)

Last reconciled with current guidelines: 2026-05-15.
References
  • KDIGO 2020 BP Management in Kidney Transplant Recipients + KDIGO 2009 Transplant Recipient Care (Kasiske AJT 2010 PMID 19845597) + 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) — PMID:19845597
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 32249009) — PMID:32249009
  • Cited evidence (PMID 26551272) — PMID:26551272
  • Cited evidence (PMID 10972386) — PMID:10972386